Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.

- Final step in Lilly's planned transition to provide only bamlanivimab and etesevimab together in the U.S. - Bamlanivimab and etesevimab together now fully available across the U.S. - Lilly, in collaboration with Amgen, expects to manufacture sufficient supply for complete global transition by